论文部分内容阅读
随着自身免疫性1型糖尿病患者的增多,寻找该类疾病的新型治疗途径也愈发显得重要。Tepli-zumab(代号:MGA-031)是一种靶向CD3T细胞表面抗原的人源化Fc突变的单克隆抗体,研究显示,其可参与T细胞激活过程,保护胰岛β细胞,从而降低胰岛素依赖。MacroGenics公司与Lilly公司合作进行
As the number of patients with autoimmune type 1 diabetes increases, a new therapeutic approach to finding such a disease becomes increasingly important. Tepli-zumab (code: MGA-031), a monoclonal antibody that targets humanized Fc mutations of CD3 T cell surface antigens, has been shown to be involved in T cell activation and protect islet β cells, thereby reducing insulin dependence . MacroGenics company and Lilly company cooperation